Exact Sciences Corporation (EXAS)
NEUTRALFundamental
39
Kurs
$-
Marktkapitalisierung
$20.03B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$3.25B
Geschäftsjahr zum 31.12.2025
Nettogewinn
$-208M
Geschäftsjahr zum 31.12.2025
Freier Cashflow
$282M
Gesamtes Eigenkapital
$2.40B
Gesamtverbindlichkeiten
$2.53B
Current Ratio
2.43
Zinsdeckungsgrad
-
Schulden/EBITDA
35.47
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$76.95
Aktueller Kurs
-
Sicherheitsmarge
-
Innerer-Wert-Spanne
$50.02 - $103.88
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
-
ROE
-8.7%
P/B-Verhältnis
8.34
P/FCF
-
Bruttomarge
69.7%
ROIC
-4.8%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
-4.8%
WACC
7.1%
ROIC − WACC
-11.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (7)
- Price CAGR 22.89%
- Gross Margin 69.7%
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 16.8%
- Net Margin Trend -6.4% vs -37.3%
Nicht bestanden (9)
- ROIC -4.8%
- P/B Ratio 8.34
- CapEx intensity
- Debt/EBITDA
- DCF valuation (Unknown)
- ROE -8.5%
- Analyst Consensus 28% Buy
- Earnings Surprise avg -111.7%
- Piotroski F-Score 2/9
Nicht verfügbar (11)
- EPS data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
Piotroski F-Score
Ernsthafte finanzielle Bedenken
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Unternehmensführung
Prüfungsrisiko
1
Vorstandsrisiko
2
Vergütungsrisiko
3
Aktionärsrechterisiko
4
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for EXAS, sourced from Markets Gazette.
- 2/23/2026POSITIVEAbbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal
Abbott Laboratories is launching a significant bond sale, in as many as eight parts, to fund its approximately $21 billion acquisition of cancer-screening company Exact Sciences Corp. This move signals Abbott's strong commitment to finalizing a strategic deal that will bolster its diagnostics portfolio. For shareholders of Exact Sciences, this development is a clear positive catalyst. Acquisitions of this magnitude are typically executed at a premium to the target's current market price, suggesting an immediate upward revaluation of the stock. Abbott's financing action validates the technology and growth potential of Exact Sciences, turning the company's intrinsic value into a tangible gain for investors as the deal progresses.
via Markets Gazette